Shopping Cart 0
Cart Subtotal
USD 0

Partnerships, Licensing, Investments and M&A Deals and Trends for November 2016 in Pharmaceuticals

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 1000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 2000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 3000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Partnerships, Licensing, Investments and M&A Deals and Trends for November 2016 in Pharmaceuticals

Summary

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for November 2016 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in November 2016. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include-North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 9

2 Pharmaceuticals & Healthcare, Global, Deal Summary 12

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, November 2016 12

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, November 2016 14

2.2.1 Abbott Labs Prices Public Offering of Notes for USD15.1 Billion 14

2.2.2 Pfizer Raises USD6 Billion in Public Offering of Notes 14

2.2.3 Bayer Raises USD4.3 Billion in Private Placement of Convertible Notes due 2019 15

2.2.4 Allergan Acquires Chase Pharma 15

2.2.5 Mitsubishi Tanabe Pharma Enters into Licensing Agreement with Kolon Life Science 16

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, November 2016 17

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, November 2016 18

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 19

3.1 Pharmaceuticals & Healthcare, Global, M&A, November 2016 19

3.1.1 Top M&A Deals in November 2016 20

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, June 2016-November 2016 21

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, November 2016 22

3.2.1 Top Equity Offering Deals in November 2016 23

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, June 2016-November 2016 24

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, November 2016 25

3.3.1 Top PE/VC Deals in November 2016 26

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, November 2016 27

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, November 2016 28

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, June 2016-November 2016 29

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2016-November 2016 30

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, November 2016 31

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, June 2016-November 2016 33

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), November 2016 34

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, November 2016 35

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), June 2016-November 2016 36

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, June 2016-November 2016 38

3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), June 2016-November 2016 39

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), June 2016-November 2016 41

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, November 2016 43

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, November 2016 43

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2016 44

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), June 2016-November 2016 45

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), June 2016-November 2016 47

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), June 2016-November 2016 49

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), June 2016-November 2016 51

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, November 2016 52

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, November 2016 53

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, November 2016 53

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 54

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, November 2016 54

5.1.1 Oncology-Deals of the Month 55

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, November 2016 57

5.2.1 Central Nervous System-Deals of the Month 58

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, November 2016 60

5.3.1 Infectious Diseases-Deals of the Month 61

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, November 2016 63

5.4.1 Cardiovascular-Deal of the Month 64

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, November 2016 66

5.5.1 Immunology-Deals of the Month 67

5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, November 2016 69

5.6.1 Gastrointestinal-Deal of the Month 70

5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, November 2016 72

5.7.1 Metabolic Disorders-Deal of the Month 73

6 Deal Summary by Geography 75

6.1 Pharmaceuticals & Healthcare, North America Deals, November 2016 75

6.1.1 North America-Deals of the Month 76

6.2 Pharmaceuticals & Healthcare, Europe, Deals, November 2016 79

6.2.1 Europe-Deals of the Month 80

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, November 2016 82

6.3.1 Asia-Pacific-Deals of the Month 83

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, November 2016 84

6.4.1 Rest of the World-Deals of the Month 85

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 86

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, June 2016-November 2016 86

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, June 2016-November 2016 87

8 Further Information 89

8.1 Methodology 89

8.2 About GlobalData 90

8.3 Disclosure information 90

8.4 Disclaimer 91


List Of Figure

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), June 2016-November 2016 12

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), November 2016 17

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), November 2016 18

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), June 2016-November 2016 19

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2016-November 2016 21

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), June 2016-November 2016 22

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2016-November 2016 24

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), June 2016-November 2016 25

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2016-November 2016 27

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), November 2016 28

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), November 2016 28

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), June 2016-November 2016 29

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), June 2016-November 2016 31

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2016-November 2016 33

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2016-November 2016 34

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2016-November 2016 36

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2016-November 2016 38

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2016-November 2016 39

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), June 2016-November 2016 41

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), June 2016-November 2016 43

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2016-November 2016 44

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2016-November 2016 45

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2016-November 2016 47

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, June 2016-November 2016 49

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), June 2016-November 2016 50

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), November 2016 51

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), June 2016-November 2016 54

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), June 2016-November 2016 57

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), June 2016-November 2016 60

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), June 2016-November 2016 63

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), June 2016-November 2016 66

Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 69

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 72

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), June 2016-November 2016 75

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), June 2016-November 2016 79

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), June 2016-November 2016 82

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), June 2016-November 2016 84

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), June 2016-November 2016 86

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), June 2016-November 2016 87


List Of Table

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 13

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, November 2016 14

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), November 2016 18

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 20

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, November 2016 20

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2016-November 2016 21

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 23

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, November 2016 23

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 24

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 26

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, November 2016 26

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, June 2016-November 2016 27

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), November 2016 29

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), June 2016-November 2016 30

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2016-November 2016 30

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), June 2016-November 2016 32

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2016-November 2016 33

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2016-November 2016 34

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), November 2016 35

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2016-November 2016 37

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2016-November 2016 40

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), June 2016-November 2016 42

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 43

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), June 2016-November 2016 44

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2016-November 2016 45

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), November 2016 48

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2016-November 2016 50

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), November 2016 52

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, November 2016 52

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, November 2016 53

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, November 2016 53

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 55

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 58

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 61

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 64

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 67

Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 70

Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 73

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 76

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 80

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 83

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 85

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), June 2016-November 2016 86

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), June 2016-November 2016 87

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials

Partnerships, Licensing, Investments and M&A Deals and Trends for November 2016 in Pharmaceuticals

Summary

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for November 2016 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in November 2016. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include-North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

READ MORE

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 9

2 Pharmaceuticals & Healthcare, Global, Deal Summary 12

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, November 2016 12

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, November 2016 14

2.2.1 Abbott Labs Prices Public Offering of Notes for USD15.1 Billion 14

2.2.2 Pfizer Raises USD6 Billion in Public Offering of Notes 14

2.2.3 Bayer Raises USD4.3 Billion in Private Placement of Convertible Notes due 2019 15

2.2.4 Allergan Acquires Chase Pharma 15

2.2.5 Mitsubishi Tanabe Pharma Enters into Licensing Agreement with Kolon Life Science 16

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, November 2016 17

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, November 2016 18

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 19

3.1 Pharmaceuticals & Healthcare, Global, M&A, November 2016 19

3.1.1 Top M&A Deals in November 2016 20

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, June 2016-November 2016 21

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, November 2016 22

3.2.1 Top Equity Offering Deals in November 2016 23

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, June 2016-November 2016 24

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, November 2016 25

3.3.1 Top PE/VC Deals in November 2016 26

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, November 2016 27

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, November 2016 28

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, June 2016-November 2016 29

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2016-November 2016 30

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, November 2016 31

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, June 2016-November 2016 33

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), November 2016 34

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, November 2016 35

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), June 2016-November 2016 36

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, June 2016-November 2016 38

3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), June 2016-November 2016 39

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), June 2016-November 2016 41

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, November 2016 43

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, November 2016 43

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2016 44

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), June 2016-November 2016 45

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), June 2016-November 2016 47

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), June 2016-November 2016 49

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), June 2016-November 2016 51

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, November 2016 52

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, November 2016 53

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, November 2016 53

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 54

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, November 2016 54

5.1.1 Oncology-Deals of the Month 55

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, November 2016 57

5.2.1 Central Nervous System-Deals of the Month 58

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, November 2016 60

5.3.1 Infectious Diseases-Deals of the Month 61

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, November 2016 63

5.4.1 Cardiovascular-Deal of the Month 64

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, November 2016 66

5.5.1 Immunology-Deals of the Month 67

5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, November 2016 69

5.6.1 Gastrointestinal-Deal of the Month 70

5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, November 2016 72

5.7.1 Metabolic Disorders-Deal of the Month 73

6 Deal Summary by Geography 75

6.1 Pharmaceuticals & Healthcare, North America Deals, November 2016 75

6.1.1 North America-Deals of the Month 76

6.2 Pharmaceuticals & Healthcare, Europe, Deals, November 2016 79

6.2.1 Europe-Deals of the Month 80

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, November 2016 82

6.3.1 Asia-Pacific-Deals of the Month 83

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, November 2016 84

6.4.1 Rest of the World-Deals of the Month 85

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 86

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, June 2016-November 2016 86

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, June 2016-November 2016 87

8 Further Information 89

8.1 Methodology 89

8.2 About GlobalData 90

8.3 Disclosure information 90

8.4 Disclaimer 91


List Of Figure

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), June 2016-November 2016 12

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), November 2016 17

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), November 2016 18

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), June 2016-November 2016 19

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2016-November 2016 21

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), June 2016-November 2016 22

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2016-November 2016 24

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), June 2016-November 2016 25

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2016-November 2016 27

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), November 2016 28

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), November 2016 28

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), June 2016-November 2016 29

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), June 2016-November 2016 31

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2016-November 2016 33

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2016-November 2016 34

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2016-November 2016 36

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2016-November 2016 38

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2016-November 2016 39

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), June 2016-November 2016 41

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), June 2016-November 2016 43

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2016-November 2016 44

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2016-November 2016 45

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2016-November 2016 47

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, June 2016-November 2016 49

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), June 2016-November 2016 50

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), November 2016 51

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), June 2016-November 2016 54

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), June 2016-November 2016 57

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), June 2016-November 2016 60

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), June 2016-November 2016 63

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), June 2016-November 2016 66

Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 69

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 72

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), June 2016-November 2016 75

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), June 2016-November 2016 79

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), June 2016-November 2016 82

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), June 2016-November 2016 84

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), June 2016-November 2016 86

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), June 2016-November 2016 87


List Of Table

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 13

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, November 2016 14

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), November 2016 18

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 20

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, November 2016 20

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2016-November 2016 21

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 23

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, November 2016 23

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 24

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 26

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, November 2016 26

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, June 2016-November 2016 27

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), November 2016 29

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), June 2016-November 2016 30

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2016-November 2016 30

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), June 2016-November 2016 32

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2016-November 2016 33

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2016-November 2016 34

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), November 2016 35

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2016-November 2016 37

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2016-November 2016 40

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), June 2016-November 2016 42

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 43

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), June 2016-November 2016 44

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2016-November 2016 45

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), November 2016 48

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2016-November 2016 50

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), November 2016 52

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, November 2016 52

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, November 2016 53

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, November 2016 53

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 55

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 58

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 61

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 64

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 67

Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 70

Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 73

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 76

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 80

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 83

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), June 2016-November 2016 85

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), June 2016-November 2016 86

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), June 2016-November 2016 87

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials